Patents Assigned to AGIOS PHARMACEUTICALS, INC
  • Inhibitors of cellular metabolic processes
    Patent number: 10329298
    Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: June 25, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Zenon D. Konteatis, Zhihua Sui, Jeremy M. Travins, Zhixiong Ye
  • Therapeutically active compounds and their methods of use
    Patent number: 10294215
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 21, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
  • IDH1 INHIBITORS FOR THE TREATMENT OF HAEMATOLOGICAL MALGNANCIES AND SOLID TUMORS
    Publication number: 20190046512
    Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.
    Type: Application
    Filed: December 2, 2016
    Publication date: February 14, 2019
    Applicants: Agios Pharmaceuticals, Inc., Celgene Corporation, Celgene Corporation
    Inventors: Michael Amatangelo, Xiaolan Hu, Anjan Thakurta, Sung Eun Choe, Bin Wu
  • Therapeutically active compounds and their methods of use
    Patent number: 10201543
    Abstract: Provided are crystalline forms of 2-Methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol mesylate useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof said compound.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: February 12, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventor: Stefan Kluge
  • Therapeutic compounds and compositions
    Patent number: 10202339
    Abstract: Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: February 12, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan
  • Methods of treatment of malignancies
    Patent number: 10188656
    Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: January 29, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Bin Wu, Sung Eun Choe
  • Therapeutically active compounds and their methods of use
    Patent number: 10172864
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: January 8, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
  • METHODS OF TREATING BRAIN TUMORS USING COMBINATION THERAPY
    Publication number: 20180353514
    Abstract: Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents.
    Type: Application
    Filed: June 12, 2018
    Publication date: December 13, 2018
    Applicant: AGIOS PHARMACEUTICALS, INC.
    Inventors: Joshua MURTIE, Nelamangala NAGARAJA, Brandon NICOLAY, David Schenkein, Katharine YEN
  • METHODS OF TREATING BRAIN TUMORS USING COMBINATION THERAPY
    Publication number: 20180353491
    Abstract: Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents.
    Type: Application
    Filed: June 12, 2018
    Publication date: December 13, 2018
    Applicant: AGIOS PHARMACEUTICALS, INC.
    Inventors: Joshua MURTIE, Nelamangala NAGARAJA, Brandon NICOLAY, David Schenkein, Katharine YEN
  • Methods of treatment of malignancies
    Patent number: 10137130
    Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 27, 2018
    Assignees: Celgene Corporation, Agios Pharmaceuticals, Inc.
    Inventors: Michael Amatangelo, Xiaolan Hu, Anjan Thakurta, Sung Eun Choe, Bin Wu
  • N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
    Patent number: 10111878
    Abstract: Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: October 30, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Jeremy Travins, Luke Utley
  • Therapeutically active compounds and their methods of use
    Patent number: 10105369
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer, for example an advanced solid tumor, such as a glioma, or angioimmunoblastic T-cell lymphoma (AITL).
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: October 23, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventor: Samuel V. Agresta
  • Methods of evaluating patients using E-cadherin or vimentin
    Patent number: 10101331
    Abstract: Methods and kits for the selection, evaluation, and/or treatment of a patient having cancer with an inhibitor of a glutamine-utilizing enzyme or a glutamine-depleting agent, by evaluating E-cadherin or vimentin expression are disclosed.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 16, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Jonathan Hurov, Sung Eun Choe, Danielle Ulanet
  • Therapeutically active compounds and their methods of use
    Patent number: 10093654
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: October 9, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Samuel V. Agresta, Chong-Hui Gu, David Schenkein, Hua Yang, Liting Guo, Zhen Tang, Jianming Wang, Yanfeng Zhang, Yan Zhou
  • Bicyclic PKM2 activators
    Patent number: 10087169
    Abstract: Compounds and compositions comprising compounds that activate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that activate PKM2 in the treatment of cancer.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: October 2, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders
  • Compounds and their methods of use
    Patent number: 10087172
    Abstract: Provided are compounds of formula (I), which can inhibit glutaminase. Pharmaceutical compositions comprising these compounds and uses as glutaminase inhibitors for treating cancers thereof are also provided.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: October 2, 2018
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Yongsheng Chen
  • Therapeutic compounds and compositions
    Patent number: 10029987
    Abstract: Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: July 24, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders, Shunqi Yan
  • Therapeutically active compounds and their methods of use
    Patent number: 10028961
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: July 24, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
  • Therapeutically active compounds and their methods of use
    Patent number: 10017495
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: July 10, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Jeremy M. Travins, Tao Guo, Li Zhang
  • Glutaminase inhibitors and method of use
    Patent number: 10011574
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: July 3, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan